{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:14:26Z","timestamp":1777389266949,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.psychres.2020.113246","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T22:38:58Z","timestamp":1592865538000},"page":"113246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis"],"prefix":"10.1016","volume":"291","author":[{"given":"Eleftheria","family":"Kopelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrto","family":"Samara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Siargkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Papazisis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michail","family":"Chourdakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1744-859X-9-20","article-title":"Global Assessment of Functioning (GAF): properties and frontier of current knowledge","volume":"9","author":"Aas","year":"2010","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I","volume":"62","author":"Adams","year":"1940","journal-title":"J. Am. Chem. Soc."},{"issue":"S7","key":"10.1016\/j.psychres.2020.113246_bib0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): conceptual and Theoretical Foundations","volume":"155","author":"Andreasen","year":"1989","journal-title":"Br. J. Psych."},{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2011.10.015","article-title":"The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates","volume":"134","author":"August","year":"2012","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2020.113246_bib0005","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/geronj\/39.2.194","article-title":"The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns","volume":"39","author":"Beller","year":"1984","journal-title":"J. Gerontol."},{"issue":"12","key":"10.1016\/j.psychres.2020.113246_bib0006","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychi."},{"issue":"7","key":"10.1016\/j.psychres.2020.113246_bib0007","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2020.113246_bib0008","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"issue":"7","key":"10.1016\/j.psychres.2020.113246_bib0009","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"7109","key":"10.1016\/j.psychres.2020.113246_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.psychres.2020.113246_bib0011","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.psychres.2020.113246_bib0012","series-title":"ECDEU Assessment Manual For Psychopharmacology","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Braz. J. Psychiatry."},{"key":"10.1016\/j.psychres.2020.113246_bib0014","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1016\/j.psychres.2020.113246_bib0015","doi-asserted-by":"crossref","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., Welch, V., 2019. Cochrane Handbook for Systematic Reviews of Interventions., 2nd ed.John Wiley & Sons, Chichester (UK).","DOI":"10.1002\/9781119536604"},{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","article-title":"How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review","volume":"269","author":"Hoch","year":"2019","journal-title":"Eur. Arch. Psychiatry. Clin. Neurosci."},{"issue":"10202","key":"10.1016\/j.psychres.2020.113246_bib0017","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psychres.2020.113246_bib0018","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.psychres.2020.113246_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006626.pub2","article-title":"Amisulpride versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database of Systematic Rev."},{"issue":"10","key":"10.1016\/j.psychres.2020.113246_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13853","article-title":"Trends in Internet Searches for Cannabidiol (CBD) in the United States","volume":"2","author":"Leas","year":"2019","journal-title":"JAMA Network Open"},{"issue":"9896","key":"10.1016\/j.psychres.2020.113246_bib0022","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"9657","key":"10.1016\/j.psychres.2020.113246_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2020.113246_bib0024","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry."},{"issue":"4","key":"10.1016\/j.psychres.2020.113246_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S2045796018000239","article-title":"Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview","volume":"27","author":"Mandolini","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"3","key":"10.1016\/j.psychres.2020.113246_bib0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: a Multicenter Randomized Controlled Trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry."},{"issue":"7","key":"10.1016\/j.psychres.2020.113246_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS. Med."},{"issue":"1","key":"10.1016\/j.psychres.2020.113246_bib0028","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"issue":"9","key":"10.1016\/j.psychres.2020.113246_bib0029","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P & T: a peer-reviewed journal for formulary management"},{"issue":"7610","key":"10.1016\/j.psychres.2020.113246_bib0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/bmj.39227.616447.BE","article-title":"Schizophrenia","volume":"335","author":"Picchioni","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2020.113246_bib0032","series-title":"8th International Conference on Early Psychosis: From Neurobiology to Public Policy","first-page":"1","article-title":"The endocannabinoid system as a pharmacological target for antipsychotic treatment and more?, in: psychiatry, E.I.i. (Ed","author":"Rohleder","year":"2012"},{"issue":"7","key":"10.1016\/j.psychres.2020.113246_bib0033","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2020.113246_bib0034","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: a Diagnostic Test Review","volume":"172","author":"Samara","year":"2015","journal-title":"Am. J. Psychiatry."},{"issue":"12","key":"10.1016\/j.psychres.2020.113246_bib0035","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/syn.20557","article-title":"Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"issue":"10","key":"10.1016\/j.psychres.2020.113246_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry."},{"issue":"5","key":"10.1016\/j.psychres.2020.113246_bib0037","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"9690","key":"10.1016\/j.psychres.2020.113246_bib0038","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.psychres.2020.113246_bib0039","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jcph.1387","article-title":"A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential","volume":"59","author":"White","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"24","key":"10.1016\/j.psychres.2020.113246_bib0040","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for Medical Use: a Systematic Review and Meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.psychres.2020.113246_bib0041","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2020.113246_bib0042","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J. Clin. Psychiatry."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120312373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120312373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:45:16Z","timestamp":1759038316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178120312373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":41,"alternative-id":["S0165178120312373"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113246","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113246"}}